OUTLOOK THERAPEUTICS INC
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other … Read more
OUTLOOK THERAPEUTICS INC (OTLK) - Net Assets
Latest net assets as of September 2025: $-32.19 Trillion USD
Based on the latest financial reports, OUTLOOK THERAPEUTICS INC (OTLK) has net assets worth $-32.19 Trillion USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($18.58 Trillion) and total liabilities ($50.77 Trillion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-32.19 Trillion |
| % of Total Assets | -173.2% |
| Annual Growth Rate | N/A |
| 5-Year Change | -698668669.57% |
| 10-Year Change | N/A |
| Growth Volatility | 161.39 |
OUTLOOK THERAPEUTICS INC - Net Assets Trend (2014–2025)
This chart illustrates how OUTLOOK THERAPEUTICS INC's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for OUTLOOK THERAPEUTICS INC (2014–2025)
The table below shows the annual net assets of OUTLOOK THERAPEUTICS INC from 2014 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | $-32.19 Trillion | -44046421.93% |
| 2024-09-30 | $-73.08 Million | -406.15% |
| 2023-09-30 | $-14.44 Million | -265.26% |
| 2022-09-30 | $8.74 Million | +89.64% |
| 2021-09-30 | $4.61 Million | +63.02% |
| 2020-09-30 | $2.83 Million | +126.24% |
| 2019-09-30 | $-10.77 Million | +48.25% |
| 2018-09-30 | $-20.81 Million | +32.27% |
| 2017-09-30 | $-30.73 Million | -490.87% |
| 2016-09-30 | $-5.20 Million | +77.92% |
| 2015-09-30 | $-23.55 Million | +19.51% |
| 2014-09-30 | $-29.26 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to OUTLOOK THERAPEUTICS INC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 60570966893571400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $538.87 Billion | % |
| Other Components | $572.98 Trillion | % |
| Total Equity | $-32.19 Trillion | 100.00% |
OUTLOOK THERAPEUTICS INC Competitors by Market Cap
The table below lists competitors of OUTLOOK THERAPEUTICS INC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ASTech Co., Ltd.
KQ:453860
|
$17.77 Million |
|
ProfilGruppen AB (publ)
ST:PROF-B
|
$17.77 Million |
|
Applus Servicios Tecnologicos
MC:APPS
|
$17.77 Million |
|
Prestige Wealth Inc.
NASDAQ:AURE
|
$17.77 Million |
|
Eildon Capital Group
AU:EDC
|
$17.75 Million |
|
Farmacias Benavides S.A.B. de C.V.
MX:BEVIDESB
|
$17.74 Million |
|
Kilitch Drugs (India) Limited
NSE:KILITCH
|
$17.74 Million |
|
SAREUM HLDGS LS-0125
F:RYH0
|
$17.74 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in OUTLOOK THERAPEUTICS INC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -73,076,510 to -32,187,661,000,000, a change of -32,187,587,923,490.
- Net loss of 62,424,863 reduced equity.
- New share issuances of 25,396,398 increased equity.
- Other factors decreased equity by 32,187,550,895,025.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-62.42 Million | -0.0% |
| Share Issuances | $25.40 Million | +0.0% |
| Other Changes | $-32.19 Trillion | -100.0% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares OUTLOOK THERAPEUTICS INC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-09-30 | $-2.19 | $0.35 | x |
| 2015-09-30 | $-250.66 | $0.35 | x |
| 2016-09-30 | $-48.34 | $0.35 | x |
| 2017-09-30 | $-204.49 | $0.35 | x |
| 2018-09-30 | $-58.78 | $0.35 | x |
| 2019-09-30 | $-11.84 | $0.35 | x |
| 2020-09-30 | $0.78 | $0.35 | x |
| 2021-09-30 | $0.60 | $0.35 | x |
| 2022-09-30 | $0.82 | $0.35 | x |
| 2023-09-30 | $-1.15 | $0.35 | x |
| 2024-09-30 | $-3.94 | $0.35 | x |
| 2025-09-30 | $-1263450.35 | $0.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently OUTLOOK THERAPEUTICS INC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -0.00%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-263.08%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 0.00% | -151.72% | 0.26x | 0.00x | $-10.87 Million |
| 2015 | 0.00% | -908.09% | 0.45x | 0.00x | $-45.04 Million |
| 2016 | 0.00% | -1788.66% | 0.13x | 0.00x | $-52.78 Million |
| 2017 | 0.00% | -1019.12% | 0.18x | 0.00x | $-35.78 Million |
| 2018 | 0.00% | -974.48% | 0.14x | 0.00x | $-28.01 Million |
| 2019 | 0.00% | -423.82% | 0.48x | 0.00x | $-33.45 Million |
| 2020 | -1246.96% | -602.01% | 0.30x | 6.98x | $-35.52 Million |
| 2021 | -1153.96% | 0.00% | 0.00x | 4.95x | $-53.62 Million |
| 2022 | -756.04% | 0.00% | 0.00x | 3.27x | $-66.93 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-57.54 Million |
| 2024 | 0.00% | -44301.22% | 0.01x | 0.00x | $-68.06 Million |
| 2025 | 0.00% | 0.00% | 0.08x | 0.00x | $3.22 Trillion |
Industry Comparison
This section compares OUTLOOK THERAPEUTICS INC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| OUTLOOK THERAPEUTICS INC (OTLK) | $-32.19 Trillion | 0.00% | N/A | $17.76 Million |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |